SVRA · Savara
Conviction · Medium · more likely to lead the S&P 500 over the next three months, by a modest margin
Note written ·
The last three months
Down 23.4% since the close; the S&P 500 is down 9.4% over the same sessions. Figures in the note can cover a different window.
Daily closes, to . Red: the note's price line under the older rule, a daily close below $4.20, set on 20 November 2026. The pale line is the 50-day average, $4.86 on .
Price line
A daily close below $4.20, under the 52-week closing low of $4.22 set on 23 October 2026, which would show the market doubting the approval or the launch; or an FDA complete response letter for Molbreevi instead of approval.
A price line, set under the rules before kill lines became business results on 20 November 2026. It stays until the note's next read replaces it; a close through it only makes the note due for a fresh read.
Research onlyNot in the portfolio.
The business · as of
Savara is a biotech company developing Molbreevi (molgramostim), an inhaled drug for autoimmune pulmonary alveolar proteinosis, a rare lung disease. It has no product sales yet and plans to sell to specialist lung doctors. Its net loss was $43 million in the quarter to 30 September 2026, according to its 10-Q.
What is changing, and what follows · as of
- What is changing now
- In April 2026 the FDA extended its priority review of Molbreevi by three months, setting an action date of 22 November 2026. The company's 10-Q, filed 9 November 2026, restates that date.
- What follows for the company
- General and administrative costs rose 93% from a year earlier to $19 million in the third quarter of 2026 as the sales team was built. Cash was $130 million at 30 September 2026, and $150 million more depends on approval.
- What follows for its customers, suppliers and competitors
- Hercules Capital (HTGC) lends up to $75 million more, and RTW Investments, a private fund, pays $75 million for a royalty, only if the drug is approved by 31 March 2027.
What the price assumes · as of
At the 19 November 2026 close (filed inputs to 9 November 2026), the shares trade at 10.7 times book value with a free-cash-flow yield of −11.4%, for an enterprise value of $1,050 million; EV/sales is not available and P/E is not meaningful. That value holds only if Molbreevi is approved and its sales grow to cover operating cash outflow, which was $130 million over the four quarters to 30 September 2026.
Key figures from the filings · Health Care
Quarter to 30 September 2026, filed 9 November 2026; valuation at the 20 November 2026 close
- Free cash flow, four quarters ($M)
- −131
- Net cash, cash less debt ($M)
- 99.4
- Free-cash-flow yield (%)
- −13.9
All filed numbers
What Savara reports to the SEC in its quarterly and annual filings. Each group states its period and filing date once; a figure dated otherwise says so. Built from the filings known on .
| Pre-tax income ($M) | Not reported |
|---|---|
| Net income ($M) four quarters: −153 | −43.0 |
| Diluted shares, change on a year (%) against the quarter to 30 September 2025 | +17.4 |
| Operating cash flow ($M) | −130 |
|---|---|
| Capital spending ($M) | 0.6 |
| Free cash flow ($M) | −131 |
| Cash and short-term investments ($M) | 130 |
|---|---|
| Debt ($M) long-term debt | 30.2 |
| Net cash, cash less debt ($M) | 99.4 |
| Deferred revenue ($M) | Not reported |
| Backlog, orders not yet delivered ($M) | Not reported |
| Receivables ($M) | Not reported |
| Inventory ($M) | Not reported |
| Shareholders' equity ($M) | 108 |
| Market value ($M) | 940 |
|---|---|
| Enterprise value, market value plus net debt ($M) | 840 |
| Enterprise value to sales (×) | Not available |
| Enterprise value to operating income (×) | Not meaningful |
| Price to earnings (×) | Not meaningful |
| Price to book value (×) | 8.7 |
| Free-cash-flow yield (%) | −13.9 |
Short interest (FINRA, settled 30 October 2026, published 10 November 2026): 14.6% of shares outstanding sold short, 12.9 days of average trading to cover, +12.3% since the previous report.
| Window | Bought | Sold |
|---|---|---|
| 90 days | Not available yet | Not available yet |
| 12 months | Not available yet | Not available yet |
The thesis
Savara's shares are modestly more likely to beat the S&P 500 over the next three months than to lag it. The case rests on one event: the FDA's action date of 22 November 2026 for Molbreevi (molgramostim), an inhaled drug for autoimmune pulmonary alveolar proteinosis (autoimmune PAP). The drug has priority review, a Phase 3 trial that met its primary endpoint, and $150 million of financing that becomes available only if it is approved. Approval removes both the regulatory question and the near-term funding question together. A complete response letter (the FDA's formal refusal to approve) would undo both.
The rating is Medium. The likelier outcome is approval, but the downside of a rejection is much larger than the upside of an approval. The company has a record of manufacturing trouble: the FDA refused to file the first application in May 2025, and OINDP News tied that refusal to manufacturing data.
Bullish and bearish views on Savara Inc.
The bull case on Savara Inc. (SVRA), in brief: positive Phase 3 under priority review. The bear case: manufacturing has failed review once.
Bull case
- Positive Phase 3 under priority review. IMPALA-2 met its primary endpoint, a statistically significant improvement in gas transfer from the lungs to the blood at 24 weeks, according to Yahoo Finance's FDA decision preview of 16 November 2026. The FDA accepted the resubmitted application under priority review in February 2026, and the drug also has Breakthrough Therapy, Fast Track and Orphan Drug designations, according to OINDP News.
- The extension raised no new issues. In April 2026 the FDA extended the review by three months, moving the action date from 22 August to 22 November 2026. The agency classed the company's answers to its information requests as a major amendment. According to the company, the extension letter cited no new safety, efficacy or manufacturing concerns.
- Approval brings in $150 million. According to the 10-Q for the quarter to 30 September 2026, filed 9 November 2026, RTW Investments will pay $75 million under a royalty agreement, and Hercules Capital will lend up to $75 million in term loans. Both require US approval by 31 March 2027. Cash and short-term investments were $130 million at 30 September 2026, against operating cash outflow of $130 million over the four quarters to that date.
- Launch and ex-US filings under way. On 12 November 2026 the company announced an employment inducement grant, a stock award to a new hire. Panabee's summary of the 10-Q says general and administrative costs rose 93% from a year earlier to $19 million in the third quarter as the sales team was built. The UK's medicines regulator accepted the marketing application on 7 April 2026, and the European Medicines Agency (EMA) validated it on 30 March 2026.
Bear case
- Manufacturing has failed review once. The FDA's May 2025 refusal to file followed questions about manufacturing data. A second rejection on the same grounds would leave the company with no product and about a year of cash.
- The cash depends on the approval. Net cash was $99 million at 30 September 2026, and net loss was $153 million over the four quarters to that date. If the drug is not approved by 31 March 2027, both financing deals lapse, and an equity raise at a lower share price is the likelier route to new funds.
- Dilution has already been heavy. The diluted share count rose 17.4% from a year earlier in the quarter to 30 September 2026. Equity was $108 million, or $0.49 a share, at that date.
- Approval may already be largely priced. A common market view is that small biotech shares often fall after an expected approval. At a market value of $1,149 million at the 19 November 2026 close, the shares already assume a drug that has no sales yet.
Price setup · as of
The shares closed at $5.21 on 19 November 2026, up from $4.72 the session before, a 10.4% rise in the last session before the action date. That close sits above the 50-day moving average of $4.88 and just below the 200-day moving average of $5.32. The 3-month change is −6.8%, measured from the 21 August 2026 close of $5.59.
The 52-week closing low is $4.22, set on 23 October 2026. The 52-week intraday high is $7.00, set on 12 December 2025; the last close is 25.6% below it. If the shares close back above the 200-day moving average after the decision, it would show the market crediting approval. If they fall below the October closing low, it would show the market doubting the approval or the launch.
The 22 November 2026 action date falls on a Saturday. The FDA can act on or before that date, so the decision may land before or after a trading session.
Catalysts ahead
- 22 November 2026: FDA action date for the Molbreevi biologics license application in autoimmune PAP. Approval opens the US launch and $150 million of conditional financing. A complete response letter would remove both and break the case.
- ~31 December 2026 (est.): UK medicines regulator decision on the Molbreevi marketing application. A UK approval would add a second market and show regulators accepting the manufacturing data.
- ~31 March 2027 (est.): European Medicines Agency decision on the Molbreevi marketing application. A European approval would widen the market and support the sales assumptions behind the share price.
What would change the view
The risks this note tracks, each with what would confirm it:
- The FDA rejects Molbreevi again over manufacturing, as it refused to file the first application in May 2025. Confirmed by: a complete response letter on or around 22 November 2026 that cites manufacturing or facility findings.
- A further delay pushes approval past 31 March 2027, so the RTW royalty and Hercules loan conditions lapse. Confirmed by: the company reporting a new action date or a missed action date after 22 November 2026.
- An equity raise after approval dilutes shareholders, adding to the 17.4% rise in diluted shares in the year to the third quarter of 2026. Confirmed by: a stock offering filed with the SEC in the weeks after the FDA decision.
- A slow launch leaves product revenue short of the Hercules loan's revenue covenant. Confirmed by: small or undisclosed Molbreevi net product revenue in the first reported quarter after launch.
What it trades with · as of
Over the next three months the shares will trade mainly on the FDA decision and the first launch figures, not on the broad market. In practice they move with small-cap biotech shares facing a single regulatory decision, not with the S&P 500. Hercules Capital (HTGC) is linked through the conditional term loan, and its exposure to Savara is small relative to its loan book. On 13 November 2026, company news reported that H.C. Wainwright had initiated coverage with a Buy rating. The only recent insider filing is a Form 4 dated 25 September 2026: the Chief Commercial Officer had 29,323 shares withheld at $5.07 to pay tax on 24 September 2026, which is not an open-market sale.
Caveats
- The RTW royalty purchase and the up to $75 million Hercules term loans require US approval of Molbreevi by 31 March 2027; without it, neither is available. Form 10-Q for the third quarter of 2026 · as of
- The amended Hercules loan sets a minimum-cash test from 1 April 2027 and a trailing net product revenue test from 30 September 2027. Form 10-Q for the third quarter of 2026 · as of
The evidence, claim by claim (7)
- Net loss was $43 million in the quarter to 30 September 2026 and $153 million over the four quarters to that date. Form 10-Q for the third quarter of 2026 · as of
- Cash and short-term investments were $130 million and long-term debt was $30 million at 30 September 2026. Form 10-Q for the third quarter of 2026 · as of
- RTW Investments' $75 million royalty purchase and up to $75 million of Hercules term loans both require US approval of Molbreevi by 31 March 2027. Form 10-Q for the third quarter of 2026 · as of
- The FDA extended the Molbreevi review by three months to a 22 November 2026 action date after classing the company's answers to its information requests as a major amendment. Savara press release on the review extension, April 2026 · as of
- The Phase 3 IMPALA-2 trial met its primary endpoint, a statistically significant improvement in gas transfer at 24 weeks. Yahoo Finance FDA Decision Watch, 16 November 2026 · as of
- The European Medicines Agency validated the Molbreevi marketing application for autoimmune PAP. Savara press release, 30 March 2026 · as of
- The diluted share count rose 17.4% from a year earlier in the quarter to 30 September 2026. Form 10-Q for the third quarter of 2026 · as of
Sources
- Savara Inc - Form 10-Q - FY2026 · sec.gov
- Savara (SVRA) Q3 2026 Earnings: Savara Nears Molgramostim PDUFA · panabee.com ·
- FDA Decision Watch: Capricor’s DMD Therapy Faces Make-Or-Break Decision, Savara’s Lung Disease Drug In The Spotlight This Week · finance.yahoo.com ·
- FDA extends review of Savara’s BLA for Molbreevi molgramostim inhalation solution for the treatment of aPAP · oindpnews.com
- Savara Announces the U.S. Food & Drug Administration (FDA) Has Extended the Review Period for the Molgramostim Inhalation Solution (Molgramostim) Biologics License Application (BLA) in Autoimmune Pul… · biospace.com
- Savara Announces European Medicines Agency (EMA) Validation of Marketing Authorization Application (MAA) for MOLBREEVI* in Autoimmune Pulmonary Alveolar Proteinosis (Autoimmune PAP) · businesswire.com ·
- Savara Announces the U.K. Medicines and Healthcare Products Regulatory Agency (MHRA) Has Accepted the MOLBREEVI* Marketing Authorisation Application (MAA) for Autoimmune Pulmonary Alveolar Proteinosi… · businesswire.com ·
Related · shared themes
NTLA
Intellia Therapeutics
Intellia Therapeutics is more likely to lag the S&P 500 over three months: the FDA decision on its hereditary angioedema gene-editing drug…
ZVRA
Zevra Therapeutics
Zevra Therapeutics is more likely to lag the S&P 500 over three months after Europe's drug committee gave a final negative opinion on…
LRMR
Larimar Therapeutics
Larimar Therapeutics is modestly more likely than not to lead the S&P 500 over three months: its nomlabofusp filing is complete and eight…
RZLT
Rezolute
Rezolute's ersodetug met the primary endpoint of its Phase 3 upLIFT study (13 responders of 16 against nine needed) and a $100 million…